Monocyte-mediated chemotherapy drug delivery in glioblastoma

Nanomedicine (Lond). 2018 Jan;13(2):157-178. doi: 10.2217/nnm-2017-0266. Epub 2017 Nov 27.

Abstract

Aim: To mechanistically prove the concept of monocyte-mediated nano drug delivery in glioblastoma (GBM).

Results: nano-doxorubicin-loaded monocytes (Nano-DOX-MC) were viable, able to cross an artificial endothelial barrier and capable of infiltrating GBM spheroids and releasing drug therein. GBM cells stimulated unloading of Nano-DOX-MC and took up the unloaded drug and released damage-associated molecular patterns. In mice with orthotopic GBM xenografts, Nano-DOX-MC resulted in much improved tumor drug delivery efficacy and damage-associated molecular patterns emission. Mechanistically, Nano-DOX was found sequestered in the lysosomal compartment and to induce autophagy, which may underlie MC's tolerance to Nano-DOX. Lysosomal exocytosis was found involved in the discharging mechanism of intracellular Nano-DOX.

Conclusion: Nano-DOX can be effectively delivered by MC in GBM and induce cancer cell damage.

Keywords: autophagy; chemotherapy; damage-associated molecular patterns; drug delivery; glioblastoma; lysosomal exocytosis; monocytes; nano-based drug.

MeSH terms

  • Animals
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / chemistry*
  • Brain Neoplasms / drug therapy*
  • Cell Survival
  • Doxorubicin / administration & dosage
  • Doxorubicin / chemistry*
  • Drug Carriers / chemistry*
  • Drug Liberation
  • Female
  • Glioblastoma / drug therapy*
  • Heterografts
  • Humans
  • Lysosomes / metabolism
  • Mice, Inbred BALB C
  • Monocytes / chemistry*
  • Nanoparticles / chemistry
  • Neoplasm Transplantation
  • Particle Size
  • Surface Properties
  • Tissue Distribution
  • U937 Cells

Substances

  • Antineoplastic Agents
  • Drug Carriers
  • Doxorubicin